Tongjitang stops production due to China earthquake

18 May 2008

Shenzhen, China-based Tongjitang Chinese Medicines Co, a specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, says that the recent earthquake in China has damaged the water piping system in its Guiyang facility and has compromised the quality of its water for production of XLGB. The firm has halted production temporarily and will update investors when additional information is available.

Xiaochun Wang, Tongjitang's chief executive, stated: "we are committed to the highest quality levels of production. Currently, we are working diligently to make sure that production will be resumed as soon as conditions allow."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight